RT Journal Article
SR Electronic
T1 A Review of Hepatocellular Carcinoma in Elderly Patients Focused on Management and Outcomes
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 1411
OP 1420
DO 10.21873/invivo.11618
VO 33
IS 5
A1 CHO, EUNAE
A1 CHO, HYUN A.
A1 JUN, CHUNG HWAN
A1 KIM, HEE JOON
A1 CHO, SUNG BUM
A1 CHOI, SUNG KYU
YR 2019
UL http://iv.iiarjournals.org/content/33/5/1411.abstract
AB Recent studies report a significant age-specific increase in hepatocellular carcinoma (HCC) development among persons over 75 years old. Therefore, there is an urgent need to determine the optimal treatment strategy in elderly patients with HCC. This systemic review examines the clinical characteristics, efficacy, and safety of first-line treatment modalities. The literature was searched regarding epidemiology and clinical outcomes in elderly patients (age ≥75 years) undergoing first-line treatment for HCC. Causative or comorbid conditions of HCC in elderly patients differed from those in younger patients. Radiofrequency ablation may be effective and safe in early stages. Surgical resection may also be feasible in the early stages for selected patients. Transarterial chemoembolization may be safe and effective for intermediate HCC, and sorafenib may be feasible in elderly patients with advanced HCC. Prospective randomized trials are needed to establish the treatment strategy for elderly patients with HCC.